BVD-523-ABC (Advanced Cancer with MEK or Atypical BRAF Alterations) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out how an experimental drug, ulixertinib, works in your body and against your cancer.

What is the Condition Being Studied?

Advanced cancer that shows certain genetic alterations and is getting worse, despite prior therapy and/or surgery.

Who Can Participate in the Study?

Adults who have tumors with a MEK or atypical BRAF alteration who:
- Have gotten worse after receiving standard therapy, OR
- Are not candidates to receive standard therapy

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Take the study drug (ulixertinib) by mouth
- Provide old tumor tissue
-Have physical exams, blood and urine tests
- Have an eye exam
- Have imaging scans (CT and/or MRI)
- Have heart tests (ECG, ECHO and/or MUGA)

Study Details

Full Title
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00106555
NCT: NCT04488003
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698